Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
December 2017

Generic vs Brand-Name Antipsychotics
For some antipsychotics, generic formulations may be less bioavailable and less efficacious than the brand-name product.

Can Lithium Decrease the Risk of Dementia?
In a study in Denmark, lithium exposure in drinking water was significantly lower in people with dementia than in controls.

Ketamine for Social Anxiety Disorder?
Preliminary data suggest that ketamine (Ketalar and others) may relieve anxiety.

Postpartum Depression: Experimental Treatment with a GABA Modulator
In a study of women with severe postpartum depression, brexanolone, a formulation of allopregnanolone, was associated with decreased depressive symptoms.

In Brief
Researchers Find Evidence of a Lymphatic System in the Brain

CME 2017
If you are interested in completing the Continuing Medical Education (CME) posttest and evaluation for 2017, please go to btpnews.com/cme.

2013-2017 Bound Volume
A 5-year bound volume with a cumulative index covering the years 2013 to 2017 is available for purchase. This volume is available on thumb drive only; no print version will be published.

Antipsychotics for First-Episode Schizophrenia
For patients with first-episode schizophrenia, second-generation antipsychotics have a broad array of side effects but differ little in efficacy.

Sweet Sorrow
This month's issue of the newsletter concludes our 40th year and marks the end of a journey.

Subscription Refunds
If you paid for a subscription past December 2017, you will receive a pro-rated refund check by the end of December. Starting December 15, 2017, a free downloadable zip file will be available at btpnews.com for all archives from 2000 to 2017.

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.